National investment loss lawyers KlaymanToskes is investigating unsuitable recommendations of investments in Tonix Pharmaceuticals Holding Corp. under the symbol TNXP by Aegis Capital and other full-service brokerage firms. The law firm urges all investors who suffered investment losses in excess of $100,000 to contact the firm immediately at 888-997-9956.
KlaymanToskes is investigating Aegis Capital and other brokerage/investment advisory firms who unsuitably recommended Tonix Pharmaceuticals Holding Corp. and other Aegis Capital-underwritten investment offerings to their customers. Aegis Capital underwrote a $5,400,000 offering of Tonix Pharmaceuticals Holding Corp. on July 16, 2019, which has had a post-offering return of -100.0% as of February 28, 2024.
A recent analysis by financial economics consulting firm SLCG determined that a multitude of offerings underwritten by Aegis Capital were issued by nano stock companies constantly on the verge of delisting and bankruptcy, and over 95% of Aegis Capital’s underwritings underperformed the average microcap stock.
Financial advisors and their firms are responsible for providing suitable investment advice and must act in the best interest of their customers. Further, brokerage firms such as Aegis Capital are required to conduct complete and accurate due diligence and have a heightened duty to disclose any potential risks to its customers. Investment firms may be held liable for any losses incurred by their customers in the event of unsuitable investment recommendations, misrepresentations or omissions of material facts, and/or an overconcentration of the customer’s portfolio in one particular investment, class, or market sector, as well as failure to conduct adequate due diligence on investment offerings underwritten by the firm.
As an investor, there are signs that you should look out for if you believe you have a claim against your broker/advisor for unsuitable investment recommendations in Aegis Capital-underwritten investments, including Tonix Pharmaceuticals Holding Corp.. These signs could potentially indicate misconduct, negligence, or investment fraud. Investors are encouraged to contact our firm immediately if you have experienced any of the following:
Some investors have close relationships with their brokers due to the time and trust built over the course of their investment relationship. However, it is crucial to remember that financial decisions should be based on careful analysis and due diligence rather than solely relying on personal relationships.
If you purchased unsuitable Tonix Pharmaceuticals Holding Corp. investments, or any other Aegis Capital-underwritten investments through your financial advisor/brokerage firm, and suffered losses in excess of $100,000, contact KlaymanToskes at 888-997-9956 or by email at investigations@klaymantoskes.com for a free and confidential consultation. We do not collect attorney’s fees unless we are able to obtain a financial recovery for you.